St. Petersburg women’s half-marathon for The Leukemia & Lymphoma Society

Taking place the weekend of November 21-22, 2009, Women’s Running St. Pete Half Marathon will benefit The Leukemia & Lymphoma Society, and will draw women from across the country. It will be St. Petersburg’s first women only half marathon. Participants can train to run or walk the half marathon through LLS’s Team In Training (TNT), the world’s first, largest and best charity sports training program. With TNT, participants join a group of supportive teammates and get four to five months of training with certified coaches, and in return, they raise funds to support blood cancer research and patient services.



“We’re excited to partner with The Leukemia & Lymphoma Society’s Team In Training,” said Dawna Stone, President and Founder of Women’s Running magazine. “Together I believe we can grow the St. Pete Women’s Half Marathon into the premier women’s half marathon.”



The Leukemia & Lymphoma Society(R) (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap